Telehealth Co. Notches First Profitable Quarter June 5, 2023 (Investorideas.com Newswire) Reliq Health Technologies announces record revenues for the three months ending March 31 and its first profitable quarter after a loss during the same quarter in 2022.

Ecuador's President Signs Decree for Bioleaching Plant Permit June 2, 2023 (Investorideas.com Newswire) Ecuador's president signs a decree clearing the way for green technology company BacTech Environmental Corp. to construct its bioleaching plant in the South American country.

Analyst Says Pharma Co. 'Meaningfully Undervalued' June 2, 2023 (Investorideas.com Newswire) "We continue to view Mindset as meaningfully undervalued," Stefan Quennevill reported in an Echelon Capital Markets research note.

Stock of Canadian Health Tech Firm Upgraded To Good June 2, 2023 (Investorideas.com Newswire) Since the previous rating, this firm has experienced improvements in its business market sentiment and technicals

Telehealth Co. Signs Contract With US Health Plan Serving 1 Million Patients May 19, 2023 (Investorideas.com Newswire) Telehealth company Reliq Health Technologies signs a contract with a U.S. health plan that operates in five states with over 3,000 doctors and more than 1 million patients.

Biopharma Co. Ceases Program to Optimize Resources May 17, 2023 (Investorideas.com Newswire) This French developer of investigative cancer therapies is focused on advanced its remaining programs and is amply funded to do so

Telehealth Co. Expands into Arkansas May 8, 2023 (Investorideas.com Newswire) Telehealth company Reliq Health Technologies signs five new contracts in four states for its iUGO platform

New CSE Biotech Stock Listing - MindBio Therapeutics Corp. (CSE: MBIO) May 4, 2023 (Investorideas.com Newswire) The common shares of MindBio Therapeutics Corp. have been approved for listing on the CSE.

Pharmaceutical Company Sets Gold Standard for New Drugs April 27, 2023 (Investorideas.com Newswire) Algernon Pharmaceuticals Inc. has received a U.S. patent for a ground-breaking new Non-Alcoholic Steatohepatitis (NASH) drug under investigation, and is developing another for refractory chronic cough (RCC).

Biotech Co. Secures Majority UK Gov Funding for Phase 3 Trial April 20, 2023 (Investorideas.com Newswire) Phase 3 trials are the last major step in new drug approval and can cost a lot to operate.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

How to Prove Wrongful Death - February 1, 2022

Healthcare Supply Chain Management Software - November 29, 2021

Overview of Biotech Stocks - What Could Happen by the End of 2021? - November 3, 2021

Consider Investing In These Disruptive Medical Companies In 2021 - April 16, 2021

Resources for Physicians and Medical Practices - December 31, 2020

Lockdown Part 2: The South African Economy and the Rand - December 15, 2020

How to Get Into Canada during COVID - November 30, 2020

The Impact of Gynecomastia on Your Mental Health and How to Deal With the Condition - September 8, 2020

Does Income Protection Cover Me for a COVID Redundancy? - August 10, 2020

Everything You Need to Know About Investing in Healthcare Stocks - March 30, 2020

The Rise Of The At-Home Testing Market - January 16, 2020

Why Do You Need Birth Injury Lawyer and How They Can Help You? - October 2, 2019

5 Key Tips For Renting a Boardroom - August 14, 2018

How to Go About Choosing a Medical Malpractice Lawyer - February 13, 2018

StageZero Life Sciences, Ltd. Special and Annual General Meeting Conference Call Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - StageZero Life Sciences, Ltd. (TSX: SZLS) ("StageZero" or the "Company") today announced that it will host a conference call as part of its Special and Annual General Meeting of Shareholders on Wednesday June 7, 2023, so that all shareholders may follow along with the proceedings of the meeting.Annual General and Special Meeting Conference CallEvent Date: Wednesday June 7, 2023Time: 2:00pm ETWebcast Link:...

Telo Genomics Presents Superior Results of Its Smoldering Multiple Myeloma Studies at ASCO 2023 Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is excited to announce that the results of its smoldering multiple myeloma (SMM) studies that were conducted in collaboration with the Mayo Clinic were presented earlier today at the American Society of Clinical Oncology (ASCO) 2023 annual meeting. A total of 178 SMM patients were included in the study. The study results revealed a superior accuracy of 80% to stratify the...

BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting Vancouver, British Columbia--(Newsfile Corp. - June 5, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce that its latest leading-edge research was presented during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting that is currently taking place in Chicago, Illinois. The poster entitled "Large retrospective validation study of...

Britannia Mining Solutions Accelerates Lab Build-Out Plan with Strategic Acquisition of Paragon Geochemical Laboratories Inc. Paragon operates an industry-leading geochemistry lab strategically located near Reno, Nevada, at the heart of one of the world's most active mining regionsFast-tracks Britannia's entry into the minerals assay market, accelerating revenue growth and positive cash flow Allows BMS to remain to position itself the forefront of the industry's transition to safer, more sustainable assay solutions Toronto, Ontario and Sparks, Nevada--(Newsfile Corp. - June 5, 2023) - Britannia Life Sciences Inc. (CSE:...

Khiron Life Sciences Agrees to $500,000 Secured Deposit Toronto, Ontario--(Newsfile Corp. - June 5, 2023) -  Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) ("Khiron" or the "Company") announced today that the Company has agreed to a $500,000 non-interesting bearing refundable deposit from 2518542 Alberta Ltd. ("251"), a company controlled by Avonlea-Drewry Holdings Inc., to be secured by all of Khiron's present and after-acquired property pursuant to a general security agreement and a pledge of Khiron's shares in its subsidiaries, Pharmadrug...

Subscribe to Biotech News